Renate Grumayer-Panzer

St. Anna Kinderspital
Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Erratum to: Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard risk acute myeloid leukemia.

Erratum to: Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard risk acute myeloid leukemia.

Journal: Haematologica
Published: July 01, 2024

Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.

Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.

Journal: Wiener klinische Wochenschrift
Published: May 29, 2023

Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.

Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.

Journal: Haematologica
Published: November 16, 2022

Copy Number Changes and Allele Distribution Patterns of Chromosome 21 in B Cell Precursor Acute Lymphoblastic Leukemia.

Copy Number Changes and Allele Distribution Patterns of Chromosome 21 in B Cell Precursor Acute Lymphoblastic Leukemia.

Journal: Cancers
Published: August 03, 2021

Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.

Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 24, 2019

Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.

Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.

Journal: Leukemia
Published: September 17, 2019

The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.

The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.

Journal: Blood advances
Published: September 06, 2019

CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia.

CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia.

Journal: Haematologica
Published: February 02, 2019

Concurrent Acute Myelofibrosis and Acute Lymphoblastic Leukemia in Childhood: Case Report and Review of the Literature.

Concurrent Acute Myelofibrosis and Acute Lymphoblastic Leukemia in Childhood: Case Report and Review of the Literature.

Journal: Journal of pediatric hematology/oncology
Published: March 21, 2018

IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 03, 2018

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 18, 2017

The enigmatic role(s) of P2RY8-CRLF2.

The enigmatic role(s) of P2RY8-CRLF2.

Journal: Oncotarget
Published: September 14, 2017
Showing 1-12 of 43

Last Updated: 09/26/2026